Roche Pauses Capital Commitments in Germany Amid Drug Discount Dispute

Daniel Steiners, head of Roche Holding AG's German operations, announced that the Swiss pharmaceutical giant has suspended all future investment decisions in Germany.

The Swiss drugmaker believes recent government austerity measures in healthcare have destroyed corporate trust and undermined long-term planning in the pharmaceutical industry.

Mandatory Rebates Erode Industry Confidence

Steiners voiced strong opposition to the GKV Contribution Rate Stabilization Act, which will raise the statutory manufacturer discount on patent-protected drugs from 7% to 15.5% starting January 2027.

While Germany's Health Ministry expects the measure to save health insurers around €12 billion by 2030, helping to close an estimated €19 billion funding gap, Steiners warned that such short-term austerity overlooks structural financing issues and could push R&D and production overseas.

Steiners also dismissed Berlin's proposed "location clause"—which offers partial rebate relief to companies with substantial R&D and manufacturing operations within Germany—as insufficient.

He insisted that piecemeal adjustments cannot replace a comprehensive industrial strategy, contrasting Germany's tightening regulatory environment with the U.S., where supportive policies and infrastructure aid are actively attracting life sciences capital.

Setback for Merz's Economic Agenda

The investment freeze is a direct blow to German Chancellor Friedrich Merz, who is actively pitching Germany to global executives at an investor summit in Berlin.

The Financial Times noted in August that Roche is not alone in withdrawing; U.S. drugmaker Eli Lilly recently halved a planned €2.3 billion production investment, while Pfizer has placed its domestic investment allocation under review, and Boehringer Ingelheim cancelled €900 million in spending.

Statutory health insurance officials strongly defended the government's reforms. Stefanie Stoff-Ahnis, deputy chair of the GKV association, insisted that pharmaceutical companies still enjoy substantial profits in Germany and warned that higher drug prices would undermine recently balanced insurance finances without delivering tangible benefits to patients.

Roche employs approximately 18,600 people in Germany and has invested around €3.8 billion since 2020 to expand its domestic base.

A company spokesperson told the Financial Times that the freeze applies only to unapproved future projects, ensuring that ongoing construction at its Penzberg biotechnology center and current staffing levels remain unaffected for now.

Roche Expands China Collaboration

Separately, Hansoh Pharmaceutical Group Co., Ltd. announced Monday a second collaboration with Roche in the antibody-drug conjugate (ADC) space.

The strategic partnership covers a broad portfolio of ADC programs, including two preclinical Hansoh ADC projects and multiple ADC programs based on targets proposed by Roche and driven by Hansoh's proprietary ADC technology platform.

Under the collaboration agreement, Hansoh will lead early development of these programs through completion of global Phase Ia clinical trials.

Roche will be responsible for further development of these programs worldwide. Hansoh will retain full rights to develop, register, and commercialize these programs in mainland China, Hong Kong, Macau, and Taiwan.

Hansoh will receive an upfront payment of $400 million and a $110 million payment at the one-year anniversary, with eligibility for milestone payments that could exceed $15 billion.